QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mendrysa, S. M. Articles by Perry, M. E. Search for Related Content PubMed PubMed Citation Articles by Mendrysa, S. M. Articles by Perry, M. E. Related Content Related Article Social Bookmarking                   What's this?

RESEARCH COMMUNICATION

Tumor suppression and normal aging in mice with constitutively high p53 activity

¹ Department of Oncology, University of Wisconsin, Madison, Wisconsin 53706, USA; ² Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA; ³ Data Management Services, National Cancer Institute, Frederick, Maryland 21702, USA; ⁴ Laboratory of Protein Dynamics and Signaling, National Cancer Institute, Frederick, Maryland 21702, USA

The p53 inhibitor murine double-minute gene 2 (Mdm2) is a target for potential cancer therapies, however increased p53 function can be lethal. To directly address whether reduced Mdm2 function can inhibit tumorigenesis without causing detrimental side effects, we exploited a hypomorphic murine allele of mdm2 to compare the effects of decreased levels of Mdm2 and hence increased p53 activity on tumorigenesis and life span in mice. Here we report that mice with decreased levels of Mdm2 are resistant to tumor formation yet do not age prematurely, supporting the notion that Mdm2 is a promising target for cancer therapeutics.

[Keywords: Aging; tumor suppression; p53; Mdm2; apoptosis; cancer therapy]

Received September 23, 2005; revised version accepted November 2, 2005.

⁵ These authors contributed equally to this work.

⁶ Present address: Department of Basic Medical Sciences, Purdue University, West Lafayette, IN 47907, USA;

⁷ Present address: Department of Comparative Biosciences, University of Wisconsin, Madison, WI 53706, USA;

⁸ Present address: Integrated Toxicology Program, Duke University, Durham, NC 27708, USA;

⁹ Present address: Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA;

¹⁰ Corresponding author.

E-MAIL perryma{at}mail.nih.gov; FAX (301) 402-1037.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article

Unleashing the power of p53: lessons from mice and men

Masha V. Poyurovsky and Carol Prives
Genes & Dev. 2006 20: 125-131. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				A. Matheu, A. Maraver, and M. Serrano The Arf/p53 Pathway in Cancer and Aging Cancer Res., August 1, 2008; 68(15): 6031 - 6034. [Abstract] [Full Text] [PDF]

				A. Bouska, T. Lushnikova, S. Plaza, and C. M. Eischen Mdm2 Promotes Genetic Instability and Transformation Independent of p53 Mol. Cell. Biol., August 1, 2008; 28(15): 4862 - 4874. [Abstract] [Full Text] [PDF]

				J. Kitagaki, K. K. Agama, Y. Pommier, Y. Yang, and A. M. Weissman Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2 Mol. Cancer Ther., August 1, 2008; 7(8): 2445 - 2454. [Abstract] [Full Text] [PDF]

				H. L. Armata, D. S. Garlick, and H. K. Sluss The Ataxia Telangiectasia Mutated Target Site Ser18 Is Required for p53-Mediated Tumor Suppression Cancer Res., December 15, 2007; 67(24): 11696 - 11703. [Abstract] [Full Text] [PDF]

				F. Rodier, J. Campisi, and D. Bhaumik Two faces of p53: aging and tumor suppression Nucleic Acids Res., December 3, 2007; 35(22): 7475 - 7484. [Abstract] [Full Text] [PDF]

				C. F. Cheok, A. Dey, and D. P. Lane Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis: a Potent Drug Combination Mol. Cancer Res., November 1, 2007; 5(11): 1133 - 1145. [Abstract] [Full Text] [PDF]

				A. Efeyan, A. Ortega-Molina, S. Velasco-Miguel, D. Herranz, L. T. Vassilev, and M. Serrano Induction of p53-Dependent Senescence by the MDM2 Antagonist Nutlin-3a in Mouse Cells of Fibroblast Origin Cancer Res., August 1, 2007; 67(15): 7350 - 7357. [Abstract] [Full Text] [PDF]

				T. Terzian, Y. Wang, C. S. Van Pelt, N. F. Box, E. L. Travis, and G. Lozano Haploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development Mol. Cell. Biol., August 1, 2007; 27(15): 5479 - 5485. [Abstract] [Full Text] [PDF]

				Y. V. Wang, M. Wade, E. Wong, Y.-C. Li, L. W. Rodewald, and G. M. Wahl Quantitative analyses reveal the importance of regulated Hdmx degradation for P53 activation PNAS, July 24, 2007; 104(30): 12365 - 12370. [Abstract] [Full Text] [PDF]

				A. J. Levine, Z. Feng, T. W. Mak, H. You, and S. Jin Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways Genes & Dev., February 1, 2006; 20(3): 267 - 275. [Abstract] [Full Text] [PDF]

				M. V. Poyurovsky and C. Prives Unleashing the power of p53: lessons from mice and men Genes & Dev., January 15, 2006; 20(2): 125 - 131. [Full Text] [PDF]

				Papers of Note Sci. Aging Knowl. Environ., January 4, 2006; 2006(1): nw1 - nw1. [Full Text]